Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian(The University of Texas MD Anderson Cancer Center), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Andrew Hendifar(Cedars-Sinai Medical Center), Edik M. Blais, Subha Madhavan(Georgetown University Medical Center), Emily E. Lyons(Pancreatic Cancer Action Network), Sara Bellakbira, Patricia DeArbeloa, Lola Rahib(Pancreatic Cancer Action Network), Davendra Sohal(University of Cincinnati), Dzung Thach, Vaibhav Sahai(University of Michigan–Ann Arbor), Jonathan R. Brody(Oregon Health & Science University), Lynn M. Matrisian(Pancreatic Cancer Action Network), Sam Mikhail(Mark H. Zangmeister Cancer Center), Vincent Chung(City of Hope)
Cited by 541
Related Papers
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
|Cancer Research|2014|7.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Metalloproteinases and their inhibitors in matrix remodeling
|Trends in Genetics|1990|1.6k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k